News
PRQR
1.860
+1.64%
0.030
ProQR director Bart Filius acquires 150,000 shares for $231,000
PUBT · 5h ago
ProQR Therapeutics Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 1d ago
ProQR Therapeutics Price Target Raised to $6.00/Share From $5.00 by Evercore ISI Group
Dow Jones · 1d ago
Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6
Benzinga · 1d ago
Analysts’ Top Healthcare Picks: ProQR (PRQR), Neurogene (NGNE)
TipRanks · 1d ago
Weekly Report: what happened at PRQR last week (0622-0626)?
Weekly Report · 1d ago
ProQR Therapeutics Is Maintained at Buy by Jones Trading
Dow Jones · 4d ago
ProQR Therapeutics Price Target Cut to $10.00/Share From $11.00 by Jones Trading
Dow Jones · 4d ago
ON Semiconductor To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday
Benzinga · 4d ago
ProQR Therapeutics Price Target Cut to $3.00/Share From $4.00 by Chardan Capital
Dow Jones · 4d ago
ProQR Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 4d ago
Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3
Benzinga · 4d ago
ProQR Therapeutics price target lowered to $10 from $14 at Raymond James
TipRanks · 4d ago
ProQR Raises $59 Million in Equity Offering and Eli Lilly Private Placement
TipRanks · 4d ago
ProQR sells 5,100,780 shares to Lilly in $9.2 million private placement at $1.81 each
PUBT · 4d ago
ProQR Prices Direct Offering And Private Placement For $59 Mln In Gross Proceeds; Stock Falls 20%
NASDAQ · 4d ago
ProQR Therapeutics price target lowered to $3 from $4 at Chardan
TipRanks · 5d ago
Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success
Benzinga · 5d ago
ProQR prices $50M stock offering; secures $9.2M investment from Eli Lilly
Seeking Alpha · 5d ago
At a glance: stocks gapping up premarket
Seeking Alpha · 5d ago
More
Webull provides a variety of real-time PRQR stock news. You can receive the latest news about Proqr Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About PRQR
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).